Search Weight Loss Topics:

Page 33«..1020..32333435..40..»

Home » Hgh » Page 33

Dividend paying stocks like Heartland Group Holdings Limited (NZSE:HGH) tend to be popular with investors, and for good reason some research suggests a significant amount of all stock market returns come from reinvested dividends. If you are hoping to live on your dividends, its important to be more stringent with your investments than the average punter. Regular readers know we like to apply the same approach to each dividend stock, and we hope youll find our analysis useful.

So you might want to consider getting our latest analysis on Heartland Group Holdingss financial health here.

In this case, Heartland Group Holdings likely looks attractive to dividend investors, given its 7.6% dividend yield and seven-year payment history. It sure looks interesting on these metrics but theres always more to the story . When buying stocks for their dividends, you should always run through the checks below, to see if the dividend looks sustainable.

Explore this interactive chart for our latest analysis on Heartland Group Holdings!

Companies (usually) pay dividends out of their earnings. If a company is paying more than it earns, the dividend might have to be cut. As a result, we should always investigate whether a company can afford its dividend, measured as a percentage of a companys net income after tax. In the last year, Heartland Group Holdings paid out 91% of its profit as dividends. With a payout ratio this high, wed say its dividend is not well covered by earnings. This may be fine if earnings are growing, but it might not take much of a downturn for the dividend to come under pressure.

From the perspective of an income investor who wants to earn dividends for many years, there is not much point buying a stock if its dividend is regularly cut or is not reliable. Heartland Group Holdings has been paying a dividend for the past seven years. Its good to see that Heartland Group Holdings has been paying a dividend for a number of years. However, the dividend has been cut at least once in the past, and were concerned that what has been cut once, could be cut again. During the past seven-year period, the first annual payment was NZ$0.04 in 2012, compared to NZ$0.13 last year. Dividends per share have grown at approximately 18% per year over this time. The dividends havent grown at precisely 18% every year, but this is a useful way to average out the historical rate of growth.

So, its dividends have grown at a rapid rate over this time, but payments have been cut in the past. The stock may still be worth considering as part of a diversified dividend portfolio.

Given that the dividend has been cut in the past, we need to check if earnings are growing and if that might lead to stronger dividends in the future. Heartland Group Holdings has grown its earnings per share at 4.7% per annum over the past five years. Still, the company has struggled to grow its EPS, and currently pays out 91% of its earnings. As they say in finance, past performance is not indicative of future performance, but we are not confident a company with limited earnings growth and a high payout ratio will be a star dividend-payer over the next decade.

To summarise, shareholders should always check that Heartland Group Holdingss dividends are affordable, that its dividend payments are relatively stable, and that it has decent prospects for growing its earnings and dividend. First, its not great to see how much of its earnings are being paid as dividends. Unfortunately, earnings growth has also been mediocre, and the company has cut its dividend at least once in the past. With this information in mind, we think Heartland Group Holdings may not be an ideal dividend stock.

Companies that are growing earnings tend to be the best dividend stocks over the long term. See what the 4 analysts we track are forecasting for Heartland Group Holdings for free with public analyst estimates for the company.

If you are a dividend investor, you might also want to look at our curated list of dividend stocks yielding above 3%.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

More:
Know This Before Buying Heartland Group Holdings Limited (NZSE:HGH) For Its Dividend - Simply Wall St

The Human Growth Hormone (hGH) research report is a valuable source of data for business strategists. It provides the Human Growth Hormone (hGH) overview with growth analysis and historical and futuristic cost revenue demand and supply data. The research analysis provides an elaborative description of the value chain and distributor analysis.

Request Sample Copy of This Report: @https://99marketresearch.com/global-human-growth-hormone-hgh-market-size-status-and-forecast-2019-2025/172424/#Free-Sample-Report

The Human Growth Hormone (hGH) market study provides comprehensive data that enhance the understanding, scope and application of this report.

The report provides a basic overview of the industry including definitions and classifications. The Human Growth Hormone (hGH) analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Prominent players of Human Growth Hormone (hGH) market:

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc):

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

This report studies the Human Growth Hormone (hGH) status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyses the top players in global market, and splits the Human Growth Hormone (hGH) By product type and applications/end industries.

Read Detailed Index of full Research Study at @ https://99marketresearch.com/global-human-growth-hormone-hgh-market-size-status-and-forecast-2019-2025/172424/

To comprehend 2018-2026 Human Growth Hormone (hGH) dynamics in the world mainly, the worldwide 2018-2026 Human Growth Hormone (hGH) is analyzed across major global regions. Human Growth Hormone (hGH) Also provides customized specific regional and country-level reports for the following areas.

North America: United States, Canada, and Mexico.

South & Central America: Argentina, Chile, and Brazil.

Middle East & Africa: Saudi Arabia, UAE, etc

The study objectives of this report are:

To study and forecast the market size of Human Growth Hormone (hGH)

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end-use and region.

To analyses and compare the market status and forecast among global major regions.

To analyses the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting market growth.

TOC-

Check here for the [emailprotected]https://99marketresearch.com/global-human-growth-hormone-hgh-market-size-status-and-forecast-2019-2025/172424/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Read more:
Human Growth Hormone (hGH) Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025 - Justnewsindustry

Transparency Market Research points out that the competitive landscape in theglobal human growth hormone marketis fairly consolidated. Players continue to focus on developing products with minimal side effects. To expand business to newer markets several vendors are looking at mergers and acquisitions.

Collaborations has become an important part of talent acquisitions for better drug development. For instance OPKO and Pfizer are collaborating to develop and sell human growth hormone hGH-CTP for treating adults and children. Some of the leading players operating in the global human growth hormone market areMerck KGaA, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, and Novartis AG.

According to the research report, the global human growth hormone market is expected to be worth US$ 5,261.5 mn by the end of 2026 in terms of revenue. During the forecast years of 2017 and 2026 the global market for human growth hormone is projected to surge at a CAGR of 6.2%.

Request Sample of Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16283

Out of the many routes of administration, the subcutaneous route of administration is projected to garner the highest revenue of US$1,600 mn by the end of 2026. It continuous to be the most preferred type of chronic growth therapy. From a geographic point of view, North America human growth hormone market is expected to remain in the leading position to strong presence of players.

Rising Incidences of Chronic Conditions amongst Children and Adults Boosts Uptake of Human Growth Market

The growing application of growth hormones in treating many diseases and conditions has created a plethora of opportunities for the global human growth hormone market. The global market for human growth hormone is also being driven by the increasing awareness about the effectiveness of growth hormones in rectifying short statures. Children suffering from congenital conditions have significantly benefited from growth hormones.

Meanwhile, adults with issues pertaining to pituitary gland have also led to a growing demand for human growth hormone therapies. Today, rising incidences of HIV/AIDS, growing research and development of long acting drugs, increasing cases of cancer, improving expenditure on healthcare, and commonly found growth hormone deficiencies have all augmented the global human growth hormone market.

The research report also points out that rising incidences of pituitary tumors, neuropsychiatric-cognitive, skeletal abnormalities, neuromuscular, cardiovascular, and metabolic abnormalities are expected to seek human growth hormone therapies as effective solutions. Majority of these ailments can be alleviated with the help of growth hormones.

The report also states that the human growth hormone therapies are predominantly used for Tuner syndrome as these treatments are designed to treat poor sexual as well as physical developments. Thus, the increasing scope of application of human growth hormones is projected to take the global market to newer heights.

Request for a Discount on Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16283

Illicit Use of Drugs Likely to Hamper Global Human Growth Hormone Market

On the flip side, the global human growth hormone market is challenged by a few elements. The high cost of these drugs and therapies is the key reason holding the market back from achieving bigger market size. Additionally, illegal usage of growth hormones amongst sportsmen has become the biggest challenge for the global human growth hormone market. The report emphatically states that the adverse side-effects of these drugs is also been a major concern for the overall market.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comResearch Blog:https://theglobalhealthnews.com/

Continue reading here:
Human Growth Hormone Market is Projected to Surge at a CAGR of 6.2% During the Forecast Years of 2017 and 2026 - Statsflash

The following article is part of Jay Jaffes ongoing look at the candidates on the BBWAA 2020 Hall of Fame ballot. Originally written for the 2019 election, it has been updated to reflect recent voting results as well as additional research. For a detailed introduction to this years ballot, and other candidates in the series, use the tool above; an introduction to JAWS can be found here. All WAR figures refer to the Baseball-Reference version unless otherwise indicated.

As much as Derek Jeter, Jorge Posada, Mariano Rivera, and Bernie Williams, Andy Pettitte was a pillar of the Joe Torre-era Yankees dynasty. The tall Texan lefty played such a vital role on 13 pinstriped playoff teams and seven pennant winners plus another trip to the World Series during his three-year run with Houston that he holds several major postseason records. In fact, no pitcher ever started more potential series clinchers, both in the World Series and the postseason as a whole.

For as important as Pettitte was to the Core Four (Williams always gets the short end of the stick on that one) that anchored five championships from 1996 to 2009, he seldom made a case as one of the games top pitchers. High win totals driven by excellent offensive support helped him finish in the top five of his leagues Cy Young voting four times, but only three times did he place among the top 10 in ERA or WAR, and he never ranked higher than sixth in strikeouts. He made just three All-Star teams.

Indeed, Pettitte was more plow horse than racehorse. A sinker- and cutter-driven groundballer whose pickoff move was legendary, he was a championship-level innings-eater, a grinder (his word) rather than a dominator, a pitcher whose strong work ethic, mental preparation, and focus visually exemplified by his peering in for the sign from the catcher with eyes barely visible underneath the brim of his cap compensated for his lack of dazzling stuff. Ten times he made at least 32 starts, a mark thats tied for seventh in the post-1994 strike era. His total of 10 200-inning seasons is tied for fourth in that same span, and his 13 seasons of qualifying for the ERA title with an ERA+ of 100 or better is tied for first with two other lefties, Mark Buehrle and CC Sabathia. He had his ups and downs in the postseason, but only once during his 18-year career (2004, when he underwent season-ending elbow surgery) was he unavailable to pitch once his team made the playoffs.

Even given Pettittes 256 career wins, he takes a back seat to two other starters on the ballot (Roger Clemens and Curt Schilling) who were better at missing bats and preventing runs, and who also had plenty of postseason success. Both of those pitchers have reasons why voters might exclude them from their ballots even while finding them statistically qualified, and the same is true for Pettitte, who was named in the 2007 Mitchell Report for having used human growth hormone to recover from an elbow injury. Between those dents and dings and the additional presence of both Roy Halladay and Mike Mussina, who were elected last year, Pettitte received just 9.9% in his ballot debut. In a less crowded field, he could build upon that, at least well enough to persist on the ballot, but he seems unlikely to make much headway towards 75% barring a significant change in the electorates attitudes towards PEDs.

About those wins: Regular readers know that I generally avoid dwelling upon pitcher win totals, because in this increasingly specialized era, they owe as much to adequate offensive, defensive, and bullpen support as they do to a pitchers own performance. While one neednt know how many wins Pettitte amassed in a season or a career to appreciate his true value, those totals have affected the popular perception of his career.

2019 BBWAA Candidate: Andy Pettitte

SOURCE: Baseball-Reference

Pettitte was born on June 15, 1972 in Baton Rouge, Louisiana. His father Tom, a police sergeant, built a mound in the familys back yard and began teaching his son by using a library book that showed how Nolan Ryan gripped his pitches. When Andy was eight, the family moved to Deer Park, Texas, a suburb of Houston, where Tom coached Andys teams right up until high school. Pettitte stood over six feet tall by his junior year at Deer Park High School, with a fastball in the low 80s and an advanced feel for mixing his pitches. By the time he was a senior, he stood 6-foot-5, but was pudgy enough to play center and nose tackle on the football team.

Though Pettitte received scholarship offers from Louisiana State University and other schools, the Yankees drafted him in the 22nd round in 1990. He did not sign, instead choosing to attend San Jacinto Junior College for a year, where he played for future Rice University coach Wayne Graham, who called him a left-handed Roger Clemens. The comparison resonated, for not only had Pettitte grown up idolizing Clemens, but Graham had coached the right-hander at San Jacinto in 1981. Graham helped transform Pettitte into a legitimate pitching prospect with a 91-93 mph fastball and better conditioning. The Yankees retained his rights up until a week before the 1991 draft, and ultimately landed him for an $80,000 bonus just before the signing deadline.

Pettitte split his first professional season (1991) between the Yankees Gulf Coast and New York-Penn League affiliates; at the latter stop, he crossed paths with Posada, also 19 years old and still primarily a second baseman. The pair spent 1992 together at A-level Greensboro of the South Atlantic League, where they were eventually joined by an 18-year-old Jeter, the Yankees 1992 first-round pick. At Greensboro, Pettitte posted a 2.20 ERA and 7.0 strikeouts per nine, and in each of his next two minor league seasons, he kept his ERAs near or below 3.00; he spent most of 1993 at High-A Prince William, with a taste of Double-A Albany-Colonie, where he returned for the start of 1994 before heading to Triple-A Columbus, where he posted a 2.98 ERA and a modest 5.7 strikeouts per nine.

In the spring of 1995, Pettitte placed 49th on Baseball Americas Top 100 prospects list, but lost the battle to be the Yankees fifth starter to Sterling Hitchcock and was sent to the bullpen; he made five relief appearances, briefly returned to Columbus, then joined the big clubs rotation when Jimmy Key suffered a shoulder injury that required surgery. He enjoyed a very solid rookie campaign, going 12-9 with a 4.17 ERA (111 ERA+) and 4.01 FIP in 175 innings en route to 2.9 WAR, helping the Yankees make the playoffs for the first time since 1981. Manager Buck Showalter gave him the ball to start Game 2 of the Division Series against the Mariners; Pettitte allowed two runs through six innings before being touched up for two more in the seventh, including the go-ahead run. The Yankees won the game in 15 innings but ultimately the lost series. The 23-year-old southpaw finished third in the AL Rookie of the Year voting, which was won by the Twins Marty Cordova.

Pettitte produced one of the biggest seasons of his career in 1996: 34 starts, 221 innings, a 3.87 ERA (129 ERA+), and an AL-high 21 wins, the last thanks to a robust 5.6 runs per game of offensive support. His 5.8 WAR ranked eighth in the AL. He did all of this while rotation-mate David Cone missed four months due to an aneurysm in his arm, Key served two DL stints, and Kenny Rogers scuffled. Pettitte made his first All-Star team and finished a very close second in the AL Cy Young race behind the Blue Jays Pat Hentgen, but not before helping the Yankees to their first championship in 18 years. After allowing four runs apiece in his Division and League Championship Series starts (both of which the Yankees won, 5-4) he delivered eight strong innings on three days rest in the ALCS Game 5 clincher against the Orioles. The Braves pounded him for seven runs in 2.1 innings in the World Series opener, but Pettitte rebounded to pitch 8.1 innings of five-hit shutout ball opposite 1996 NL Cy Young winner John Smoltz, a performance that in 2015 he called the best game of my career. The Yankees eked out a 1-0 victory and took a three-games-to-two series lead; they would win in six games.

Though he won only 18 games, Pettitte actually had a better season in 1997, when he made a league-high 35 starts and threw a career-high 240.1 innings with a 2.88 ERA (156 ERA+, both good for fourth in the league) and just seven homers allowed (a league-best 0.3 per nine). His 8.4 WAR ranked second in the league behind the Cy Young-winning Clemens, but he finished just fifth in the voting. He was lousy in the postseason, getting rocked for 11 runs in 11 and two-thirds innings by the Indians in his Division Series starts, both losses. It would be five years before the Yankees took such an early vacation in October again.

In three major league seasons, Pettitte had established himself as one of the games top starters, thanks in part to his development of a nasty cut fastball. His 16.9 WAR for the period ranked sixth in the majors from 1995-1997 behind only Greg Maddux, Clemens, Kevin Brown, Randy Johnson, and Pedro Martinez. Hed done it while pitching through a sore elbow, dating back to a three-inning relief stint in Baltimore on May 1, 1997, a day after getting torched for nine runs in one-plus inning. But whether it was his elbow or his over-reliance on his sinker-cutter combo at the expense of his curve and changeup, his performance took a significant step back even as the fate of the Yankees improved. From 1998-2000, while the Yankees won three straight championships, Pettitte averaged 32 starts and 204 innings, albeit with a 4.42 ERA (105 ERA+) and just a 1.53 strikeout-to-walk ratio, down from 2.21 for the three years prior. He was still good enough to average 2.8 WAR in that span, but the Yankees pondered trading him as he grew more expensive.

In July 1999, as the trade deadline loomed, the Yankees and Phillies neared a deal that would send Pettitte (then carrying a 5.65 ERA) to Philadelphia in exchange for three prospects including pitcher Adam Eaton and outfielder Reggie Taylor. In an organizational clash, Torre, pitching coach Mel Stottlemyre, and general manager Brian Cashman won out over owner George Steinbrenner and his cabal of Tampa-based advisors, who wanted to turn the rotation spot over to the immortal Ed Yarnall. Pettitte stayed, began working out with Clemens (who had been acquired in the spring) and allowed just three runs over his next four starts totaling 31 innings. That winter, he signed a three-year, $25.5 million extension with an $11.5 million club option for 2003.

As uneven as the 1998-2000 seasons were for Pettitte, he did place fourth in the AL Cy Young voting with the best of those years (2000: 19-9, 4.35 ERA, 3.6 WAR). During that stretch, he delivered eight quality postseason starts out of 11 with a combined 3.26 ERA; the Yankees went 10-1 in those starts, rallying to win even when he took early exits in Game 3 of the 1999 World Series against the Braves and Game 5 of the 2000 Division Series against the As. He threw seven shutout innings in Game 4 of the 1998 World Series against the Padres, helping the team complete a sweep, and made good starts in Games 1 and 5 in the 2000 Subway Series against the Mets. He left the latter tied at 2-2 through seven innings; the Yankees plated two runs in the ninth and Rivera closed it out for the teams third straight championship.

The work with Clemens began to rub off on Pettitte. In 2001, his fastball showed more zip, he worked inside more often, posted career-best strikeout and walk rates (7.4 and 1.8 per nine), brought his ERA below 4.00 (3.99) with a FIP nearly a run lower (3.02), and made his second All-Star team. He pitched well in his first three postseason starts agains the As and Mariners, allowing just five runs in 20.2 innings, and hung with the Diamondbacks Johnson for six innings in his World Series Game 2 start, entering the seventh trailing 1-0 before serving up a three-run homer to Matt Williams.

After losing the first two games in Arizona, the Yankees won three straight in New York to position themselves for their fourth straight title. Pettitte again took the ball opposite Johnson but was pummeled for six runs in two-plus innings; on ESPN Radios international broadcast, analyst Rick Sutcliffe noticed that he was tipping his pitches by double-pumping on every fastball from the stretch. The Yankees didnt discover the problem until it was too late; they lost both Game 6 and thanks to a two-run rally against Rivera Game 7 as well.

While elbow, back, and groin injuries sent Pettitte to the DL every year from 1999 through 2001, the 2002 season brought his first major injury, a bout of tendonitis that sidelined him for two months, from mid-April to mid-June. Limited to 22 starts, he nonetheless went 13-5 with a 3.27 ERA (135 ERA+ in 134.2 innings), and while he lasted just three innings in his lone postseason start against the Angels, the Yankees picked up his option that winter. Pettitte rewarded them with another strong, workhorse season, though his 21-8 record and 7.8 strikeouts per nine were flashier than the other numbers (4.02 ERA, 110 ERA+, 3.1 WAR, his fourth straight season between 3.1 and 3.6). In the best October showing of his career, he posted a 2.10 ERA in five starts, allowing more than two runs just once. He whiffed a postseason career high 10 Twins in his Division Series start, and came within one out of a shutout in Game 2 of the World Series before the Marlins plated an unearned run. Though he allowed just two runs (one earned) in seven innings in Game 6, Josh Beckett shut out the Yankees on five hits, giving the upstart Marlins a championship.

In December 2003, Pettitte shocked the baseball world by returning home to Texas. He did so by bypassing a three-year, $39 million offer from the Yankees in favor of a heavily backloaded, three-year, $31.5 million deal with the Astros. He wanted to go home to Houston, said Steinbrenner. And I admire him for wanting to be with his family. He couldnt do that in New York. He was a great competitor for me.

Soon joined in Houston by Clemens, whom hed coaxed out of retirement, Pettitte made just 15 starts in 2004 due to forearm woes that culminated in season-ending surgery to repair a torn flexor tendon. He returned better than ever in 2005, going 17-9 with a career-best 2.39 ERA (177 ERA+, with both marks second in the NL behind Clemens) and 6.8 WAR (fourth in the league). During one stretch in June and July, he allowed no more than one earned run in eight straight starts. His postseason performance wasnt great (4.26 ERA in 25.1 IP), as he wound up on the losing end three times while making four quality starts. The Astros, in their first World Series appearance, were swept by the White Sox.

Pettitte made a league-high 35 starts in his final year in Houston, but battled elbow tendonitis, and his ERA ballooned to 4.20 (106 ERA+), with his WAR dipping to 1.5. He had other problems as well. In October 2006, the Los Angeles Times published a report citing an affidavit from former Yankees pitcher Jason Grimsley, who alleged that both Pettitte and Clemens had used performance-enhancing drugs, and that he himself had obtained amphetamines, anabolic steroids, and human growth hormone from Brian McNamee, a former Yankees trainer who maintained a close working relationship with both pitchers. Pettitte vehemently denied the allegations, saying, Ive never used any drugs to enhance my performance on the baseball field before.

In December, the 34-year-old lefty agreed to return to the Yankees on a one-year, $16 million deal with a $16 million player option for 2008. On September 19, near the end of a typical season (15-9, 4.05 ERA, 5.9 K/9, 3.8 WAR), he beat the Orioles with a seven-inning, one-run performance to claim the 200th victory of his career. His 6.1 shutout innings against the Indians in Game 2 of the Division Series went for naught when Joba Chamberlain was devoured by a horde of midges.

Feeling the pull of family and mulling retirement, Pettitte declined his player option, mainly to allow the team to free up a roster spot while he deliberated. On December 3, he agreed to return at that same salary, but nine days later, his name was among the 89 included in the Mitchell Report. Two days later, he admitted to injecting HGH obtained through McNamee to recover from his 2002 elbow injury. In 2002 I was injured. I had heard that human growth hormone could promote faster healing for my elbow, he said in a statement released to the Associated Press. I felt an obligation to get back to my team as soon as possible. For this reason, and only this reason, for two days I tried human growth hormone. Though it was not against baseball rules, I was not comfortable with what I was doing, so I stopped.

Pettittes name remained in the headlines when Clemens appeared before Congress to challenge the findings pertaining to him in the report in February 2008. Pettitte said in a statement that Clemens had told him of using HGH nearly 10 years earlier, and that McNamee had told him that Clemens used steroids in 2003 or 04. Clemens claimed Pettitte misremembered.

On the field, Pettitte scuffled. While his 4.54 ERA was not a career worst, his 97 ERA+ was; it was the only time in his 18-year career that he allowed runs at a worse-than-average clip (his 3.71 FIP, his best in three years, told a different story). The Yankees missed the playoffs for the first time since the 1994 players strike, which triggered a major spending spree; $420 million worth of commitments brought Sabathia, A.J. Burnett, and Mark Teixeira to the Bronx. Pettitte, working on an incentive-laden one-year deal, served as a solid number three starter behind the two newcomers, rebounding to a 4.16 ERA and 3.4 WAR, then turned in one of his most memorable postseason runs. Though his overall 3.52 ERA in five starts totaling 30.2 innings wasnt remarkable, he joined the 2004 Red Soxs Derek Lowe by winning three clinching games in a single postseason, over the Twins (Division Series), Angels (ALCS), and Phillies (World Series).

Though he made the AL All-Star team on the strength of an 11-2, 2.70 ERA first half, Pettittes 2010 was abbreviated by a groin strain that sidelined him for two months and limited him to just one September start longer than four innings. Nonetheless, he turned in a pair of seven-inning, two-run starts in the Yankees Division Series Game 2 victory over the Twins and their ALCS Game 3 defeat by the Rangers. Again deliberating on the retirement question, he pulled the plug in early February, just before pitchers and catchers reported.

Though he sat out all of 2011, Pettitte could not stay retired. In March 2012, the 39-year-old southpaw quietly agreed to return to the Yankees who had, in essence, left the light on for him on a $2.5 million deal. He returned to the majors on May 13, and pitched as well as ever (3.22 ERA, 9.1 K/9) until a one-hopper off the bat of the Indians Casey Kotchman fractured his left fibula. After missing nearly three months, he made a three-start September tuneup followed by a pair of good postseason starts totaling five runs allowed in 13.2 innings. Alas, he wound up on the short end both times, and the Yankees bowed to the Tigers in the ALCS.

Still hankering for more, Pettitte returned for his age-41 season, and for the first time since 2009 made 30 starts, finishing with a 3.74 ERA and 2.2 WAR in 185.1 innings. Unlike Rivera, who received a grand farewell tour that culminated with Jeter and Pettitte pulling him from his final appearance, Pettitte didnt announce his intentions until September 20, 2013. He threw seven innings of two-run ball against the Giants in his final Yankee Stadium start two days later, and then a complete-game five-hitter against the Astros in Houston, his home away from home, on September 28.

From a Hall of Fame standpoint, Pettittes claim rests on a high win total, very good run prevention after adjusting for his park and league, and a strong postseason resum, all of which are worth a closer look. First, the wins. Pettittes total of 256 ranks 42nd all-time, and is higher than 32 of the 65 enshrined starters, including Halladay (203), and 2018 Modern Baseball Era Committee honoree Jack Morris (254). However, 256 wins does not guarantee a spot in the Hall; there are eight pitchers with more on the outside looking in, including Clemens (354) and a pair of pitchers who spent more than a quarter-century in the majors, Tommy John (284) and Jim Kaat (283).

Wins, of course, are the product not just of a pitchers skill at run prevention but also of the support he receives from his offense, his defense, and his bullpen. In Pettittes case, prior to his original retirement he received offensive support that was about 10 percent better than the park-adjusted league average. Thats according to research done for the Baseball Prospectus book Extra Innings by Colin Wyers and myself in the fall of 2011, with said support for all starters defined simply as the runs scored on the day (or night) the starter pitched, and therefore available via game logs back into the 19th century. Wyers and I found just 12 Hall of Fame starters with better support, led by Chief Bender (117).

Pettitte was less well-supported by his defenses, in that he had a .312 career batting average on balls in play where the MLB average was .298; his FIP (3.74) is thus lower than his ERA (3.85). Bullpen support? Pettitte and Rivera the best ever at his job combined to set a record for teaming up, with Rivera saving 72 of Pettittes wins, far beyond the 57 wins of Oaklands Bob WelchDennis Eckersley combo.

Pettittes career ERA would be the second-highest in the Hall, in front of only Morris, but the adjustments for park and league are everything in this case. Pettitte has a 117-105 edge on Morris in ERA+. His 117 ERA+ matches that of Hall of Famer Gaylord Perry, who ranks 43rd among enshrined starters, and its two points better than Jim Bunning, Steve Carlton, Phil Niekro, Fergie Jenkins, and Eppa Rixey, who are tied for 45th. All but Bunning threw at least 1,000 more innings than Pettitte.

Postseason-wise, the frequency of the Yankees participation in the three-tiered playoff format whose introduction coincided with the start of Pettittes career helped him set records for starts (44), innings (276.2) and wins (19, against 11 losses); meanwhile, hes second in strikeouts (183). While Pettitte certainly hit some high notes within that large body of work while helping the Yankees win five championships, he also had some duds, including seven starts with five or more runs allowed, only one of which went longer than five innings. His 3.81 postseason ERA is a ringer for his regular season mark; his 4.06 World Series ERA in 13 World Series starts (the second-highest total behind Whitey Fords 22) slightly worse; hes tied for seventh in World Series strikeouts (56) and eighth in innings (77.2) and wins (five). His ERA in his record 12 potential postseason series clinchers: 3.95 (the Yankees won eight); in four potential World Series clinchers: 3.68 (the Yankees won three). Cool stuff, but he was more like the second coming of Andy Pettitte than he was Schilling or Madison Bumgarner.

In terms of WAR, Pettittes career total of 60.2 is 13.1 WAR short of the standard at the position. Hes 64th 22 spots lower than his win total, remember and behind 44 of the 65 enshrined starters. Among those elected by the BBWAA, only Ford (56.9) and Catfish Hunter (40.9) threw at least 3,000 innings, where Dazzy Vance (60.1) and Bob Lemon (48.2) fell just short, with Sandy Koufax (49.0) short of 2,500 and Dizzy Dean (45.6) short of 2,000. Thats not a great argument in Pettittes favor.

Nor is the fact that his 34.1 peak score is tied for 170th with one Thornton Lee, 0.2 ahead of Don Sutton, whose peak is the lowest among BBWAA honorees. Pettittes 47.1 JAWS ranks 91st, ahead of only Ford (45.7), Dean (44.9), Lemon (43.3), and Herb Pennock (40.9) among BBWAA honorees. Of the currently active starters whose progress towards Cooperstown Ive been monitoring, hes well behind Justin Verlander, Zack Greinke, Clayton Kershaw, Max Scherzer, and Sabathia.

Thus, based upon both traditional and advanced metrics, Pettitte would represent a rather weak choice for the Hall of Fame and I say that as somebody who had a considerable emotional investment in his career as a fan and would like nothing more than to find a rationale for electing him. I dont see one, and thats even while consigning his Mitchell Report-related transgressions to the Wild West era of the games drug problems, where if MLB couldnt punish him, I dont think voters should do so either.

Given all of that as well as the presence of two starters with stronger (albeit controversial) cases on the ballot, its tough to find a particularly compelling rationale to vote for Pettitte. Just 9.9% of voters did last year, and of the voters in Ryan Thibodauxs Ballot Tracker, just three said that if they had more than 10 slots, they would have included Pettitte as well, which does not portend a groundswell of coming support.

I suspect that some voters will see the elections of Mussina and Halladay both well short of 300 wins as pushing the door a bit more widely open for Pettitte, but both were much stronger at run prevention, and generally more decorated and celebrated. That said, it does appear as though his candidacy will persist. And while hes probably not a fit for Cooperstown, flags fly forever, and hell always be fondly remembered in the Bronx.

Go here to see the original:
JAWS and the 2020 Hall of Fame Ballot: Andy Pettitte - FanGraphs

The Monoclonal antibodies (mAbs) Biosimilars Market report gives a purposeful depiction of the area by the practice for research, amalgamation, and review of data taken from various sources. The market analysts have displayed the different sidelines of the area with a point on recognizing the top players (Biocon, Celltrion, Dr. Reddys Laboratories, Hospira, 3SBio, Accord Healthcare, AET Biotech, Allergan, Amega Biotech, Others) of the industry. The Monoclonal antibodies (mAbs) Biosimilars market report correspondingly joins a predefined business market from a SWOT investigation of the real players. Thus, the data summarized out is, no matter how you look at it is, reliable and the result of expansive research.

This report mulls over Monoclonal antibodies (mAbs) Biosimilars showcase on the classification, for instance, application, concords, innovations, income, improvement rate, import, and others (Anti-Cancer, Anti-Inflammatory/Autoimmune) in the estimated time from 20192025 on a global stage. In like manner, the overall Monoclonal antibodies (mAbs) Biosimilars market report reveals knowledge identified with the type of product, its applications, customers, prime players, and various components agreeing with the account. This first data demonstrates critical contenders and their definite picture of the general Monoclonal antibodies (mAbs) Biosimilars market. Other than this, the report further demonstrates expected market power, challenges, and prospects in the Monoclonal antibodies (mAbs) Biosimilars market.

Request for Sample Report @http://www.marketresearchstore.com/report/global-monoclonal-antibodies-mabs-biosimilars-market-2019-by-494894#RequestSample

Types Segment:Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb), Insulin, Interferon (IFN), Others

Key Market Features:

The scope of the report extends from market eventualities to a comparative rating between major players, price, and profit of the required market regions. This makes available the holistic view on competitive analysis of the market. Some of the top players involved in the market are profiled completely in a systematic manner. In the end, the report concludes the new project, key development areas, business overview, product/services specification, SWOT analysis, investment feasibility analysis, return analysis and development trends. The study also presents a round-up of vulnerabilities in which companies operating in the market and must be avoided in order to enjoy sustainable growth through the course of the forecast period.

The study provides a comprehensive analysis of the key market factors and their latest trends, along with relevant market segments and sub-segments. Market size is calculable in terms of revenue (USD Million) production volume during the forecast period.

Global Monoclonal antibodies (mAbs) Biosimilars Market report provides a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. The report also looks at the influential factors that are affecting the development of the Global Automotive Bumpers Market. This statistical report also offers various internal and external driving as well as restraining factors for this research report.

Get Exclusive Buying report:http://www.marketresearchstore.com/report/global-monoclonal-antibodies-mabs-biosimilars-market-2019-by-494894#InquiryForBuying

Essential application areas of Monoclonal antibodies (mAbs) Biosimilars are also measured on the basis of their performance. Market forecasts along with the statistical nuances presented in the report render an insightful view of the Monoclonal antibodies (mAbs) Biosimilars market. The market study on report studies present as well as coming aspects of the Monoclonal antibodies (mAbs) Biosimilars Market mainly based upon factors on which the companies contribute to the market evolution, key trends, and segmentation analysis.

The scope of the report extends from market eventualities to a comparative rating between major players, price, and profit of the required market regions. This makes available the holistic view on competitive analysis of the market. Some of the top players involved in the market are profiled completely in a systematic manner.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

View post:
Global Monoclonal antibodies (mAbs) Biosimilars Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - The Industry Press...

If you own shares in Heartland Group Holdings Limited (NZSE:HGH) then its worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks on the market.

Some stocks are more sensitive to general market forces than others. Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). While we should keep in mind that Warren Buffett has cautioned that Volatility is far from synonymous with risk, beta is still a useful factor to consider. To make good use of it you must first know that the beta of the overall market is one. Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

See our latest analysis for Heartland Group Holdings

Given that it has a beta of 0.84, we can surmise that the Heartland Group Holdings share price has not been strongly impacted by broader market volatility (over the last 5 years). This suggests that including it in your portfolio will reduce volatility arising from broader market movements, assuming your portfolios weighted average beta is higher than 0.84. Many would argue that beta is useful in position sizing, but fundamental metrics such as revenue and earnings are more important overall. You can see Heartland Group Holdingss revenue and earnings in the image below.

Heartland Group Holdings is a small cap stock with a market capitalisation of NZ$987m. Most companies this size are actively traded. Small companies can have a low beta value when company specific factors outweigh the influence of overall market volatility. That might be happening here.

Since Heartland Group Holdings is not heavily influenced by market moves, its share price is probably far more dependend on company specific developments. It could pay to take a closer look at metrics such as revenue growth, earnings growth, and debt. This article aims to educate investors about beta values, but its well worth looking at important company-specific fundamentals such as Heartland Group Holdingss financial health and performance track record. I urge you to continue your research by taking a look at the following:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
Does Heartland Group Holdings Limited (NZSE:HGH) Have A High Beta? - Simply Wall St

Transparency Market Research points out that the competitive landscape in theglobal human growth hormone marketis fairly consolidated. Players continue to focus on developing products with minimal side effects. To expand business to newer markets several vendors are looking at mergers and acquisitions. Collaborations has become an important part of talent acquisitions for better drug development. For instance OPKO and Pfizer are collaborating to develop and sell human growth hormone hGH-CTP for treating adults and children. Some of the leading players operating in the global human growth hormone market are Merck KGaA, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, and Novartis AG.

According to the research report, the global human growth hormone market is expected to be worth US$ 5,261.5 mn by the end of 2026 in terms of revenue. During the forecast years of 2017 and 2026 the global market for human growth hormone is projected to surge at a CAGR of 6.2%. Out of the many routes of administration, the subcutaneous route of administration is projected to garner the highest revenue of US$1,600 mn by the end of 2026. It continuous to be the most preferred type of chronic growth therapy. From a geographic point of view, North America human growth hormone market is expected to remain in the leading position to strong presence of players.

Request a Sample of Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16283

Rising Incidences of Chronic Conditions amongst Children and Adults Boosts Uptake of Human Growth Market

The growing application of growth hormones in treating many diseases and conditions has created a plethora of opportunities for the global human growth hormone market. The global market for human growth hormone is also being driven by the increasing awareness about the effectiveness of growth hormones in rectifying short statures. Children suffering from congenital conditions have significantly benefited from growth hormones. Meanwhile, adults with issues pertaining to pituitary gland have also led to a growing demand for human growth hormone therapies. Today, rising incidences of HIV/AIDS, growing research and development of long acting drugs, increasing cases of cancer, improving expenditure on healthcare, and commonly found growth hormone deficiencies have all augmented the global human growth hormone market.

The research report also points out that rising incidences of pituitary tumors, neuropsychiatric-cognitive, skeletal abnormalities, neuromuscular, cardiovascular, and metabolic abnormalities are expected to seek human growth hormone therapies as effective solutions. Majority of these ailments can be alleviated with the help of growth hormones. The report also states that the human growth hormone therapies are predominantly used for Tuner syndrome as these treatments are designed to treat poor sexual as well as physical developments. Thus, the increasing scope of application of human growth hormones is projected to take the global market to newer heights.

Request for a Discount on Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16283

Illicit Use of Drugs Likely to Hamper Global Human Growth Hormone Market

On the flip side, the global human growth hormone market is challenged by a few elements. The high cost of these drugs and therapies is the key reason holding the market back from achieving bigger market size. Additionally, illegal usage of growth hormones amongst sportsmen has become the biggest challenge for the global human growth hormone market. The report emphatically states that the adverse side-effects of these drugs is also been a major concern for the overall market.

View original post here:
Human Growth Hormone Market is Projected To Touch a Valuation of US$1,600 mn by the End of 2026 - The Denton Chronicle

Transparency Market Research points out that the competitive landscape in theglobal human growth hormone marketis fairly consolidated. Players continue to focus on developing products with minimal side effects. To expand business to newer markets several vendors are looking at mergers and acquisitions. Collaborations has become an important part of talent acquisitions for better drug development. For instance OPKO and Pfizer are collaborating to develop and sell human growth hormone hGH-CTP for treating adults and children. Some of the leading players operating in the global human growth hormone market are Merck KGaA, Eli Lilly and Company, Pfizer Inc., Novo Nordisk A/S, and Novartis AG.

According to the research report, the global human growth hormone market is expected to be worth US$ 5,261.5 mn by the end of 2026 in terms of revenue. During the forecast years of 2017 and 2026 the global market for human growth hormone is projected to surge at a CAGR of 6.2%. Out of the many routes of administration, the subcutaneous route of administration is projected to garner the highest revenue of US$1,600 mn by the end of 2026. It continuous to be the most preferred type of chronic growth therapy. From a geographic point of view, North America human growth hormone market is expected to remain in the leading position to strong presence of players.

Request a Sample of Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16283

Rising Incidences of Chronic Conditions amongst Children and Adults Boosts Uptake of Human Growth Market

The growing application of growth hormones in treating many diseases and conditions has created a plethora of opportunities for the global human growth hormone market. The global market for human growth hormone is also being driven by the increasing awareness about the effectiveness of growth hormones in rectifying short statures. Children suffering from congenital conditions have significantly benefited from growth hormones. Meanwhile, adults with issues pertaining to pituitary gland have also led to a growing demand for human growth hormone therapies. Today, rising incidences of HIV/AIDS, growing research and development of long acting drugs, increasing cases of cancer, improving expenditure on healthcare, and commonly found growth hormone deficiencies have all augmented the global human growth hormone market.

The research report also points out that rising incidences of pituitary tumors, neuropsychiatric-cognitive, skeletal abnormalities, neuromuscular, cardiovascular, and metabolic abnormalities are expected to seek human growth hormone therapies as effective solutions. Majority of these ailments can be alleviated with the help of growth hormones. The report also states that the human growth hormone therapies are predominantly used for Tuner syndrome as these treatments are designed to treat poor sexual as well as physical developments. Thus, the increasing scope of application of human growth hormones is projected to take the global market to newer heights.

Request for a Discount on Human Growth Hormone Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16283

Illicit Use of Drugs Likely to Hamper Global Human Growth Hormone Market

On the flip side, the global human growth hormone market is challenged by a few elements. The high cost of these drugs and therapies is the key reason holding the market back from achieving bigger market size. Additionally, illegal usage of growth hormones amongst sportsmen has become the biggest challenge for the global human growth hormone market. The report emphatically states that the adverse side-effects of these drugs is also been a major concern for the overall market.

Go here to read the rest:
Human Growth Hormone Market is Expected To See Opportunities Worth US$1600 mn by the End of 2026 - Kentucky Reports

FLORHAM PARK, N.J. (AP) LeVeon Bell is throwing a flag on the NFLs drug testing policy.

The New York Jets running back says Wednesday is upset he has been randomly selected five times this season by the league to take tests for performance-enhancing drugs.

I done had 5 random HGH blood test in 10 weeks, Bell tweeted. (at)NFL Im not doing another after today, whatever yall lookin for it obviously aint there.

Bell doubled down on his Twitter comment after practice, saying its getting weird and reiterating that he will not take additional tests this season although he stopped short of saying the league is targeting him with the testing.

Im not going to say all that, Bell said in the locker room. Im just saying Im not doing it no more. Theyre not getting no more of my blood. They can use the blood theyve got right now.

The random drug testing is part of a collectively bargained policy between the NFL and NFL Players Association. An independent administrator determines via a computer program which players are tested each week.

Is it random, though? Bell said. Why do I feel like every time theyre here doing the HGH testing, I get picked?

Per NFL rules, players with no previous violations of the policy on performance enhancers wont be tested more than six times in a calendar year.

Weve been playing the season for 10 weeks and Ive been tested five times for HGH, Bell said. On average, its like once every two weeks, right? Every two weeks, you all been testing me and havent found nothing, so what are yall looking for?

I just dont understand.

If Bell does get randomly selected for a sixth test over the last five weeks of the season and he refuses to take it, the league could consider it a failed test and choose to discipline him with suspension a possibility.

If we have to cross that bridge, well cross that bridge when we get there, Bell said.

Bell wrote on Twitter hell refuse to have the league stick me with dirty needles. He clarified that comment saying he simply dislikes needles, in general, and prefers urine testing.

You want me to pee in a cup, I can do that all day, he said. Just, I ain't trying to do it with needles. Needles, you can get that away from me.

Bell was suspended by the NFL for two games in 2014 while he was with Pittsburgh after he was charged with marijuana possession and DUI, a violation of the leagues substance abuse policy. He was also suspended four games in 2016 for missing a test.

He signed with the Jets last March after sitting out last season in a contract dispute with Pittsburgh. Bell made headlines this summer when he was forced to miss portions of training camp practices on consecutive days to take league-mandated tests.

Bell is off to the worst start of his career, averaging just 3.2 yards per carry. He has also yet to rush for more than 100 yards in a game this season. Bell is second on the team in receptions with 46 for 309 yards and one TD.

NOTES: RT Chuma Edoga (ankle), S Matthias Farley (quadriceps), LB C.J. Mosley (groin), CB Darryl Roberts (calf), LB Paul Worrilow (quadriceps) all did not practice. ... DE Henry Anderson (shoulder), LT Kelvin Beachum (ankle), LB Brandon Copeland (hip, thumb), LB Neville Hewitt (neck, knee), G Alex Lewis (elbow, shoulder), NT Steve McLendon (neck) and WR Demaryius Thomas (hamstring) were limited.

___

More AP NFL: https://apnews.com/NFL and https://twitter.com/AP_NFL

View post:
Jets Bell rips NFL for random 5th HGH test - San Antonio Express-News

The New York Giants, led by rookie quarterback Daniel Jones, meet the Chicago Bears, led by quarterback Mitchell Trubisky, in an NFC Week 12 NFL football game on Sunday, November 24, 2019 (11/24/19) at Soldier Field in Chicago, Illinois.

Check the scoreboard below for up-to-the-minute scoring and stats.

Giants running back Saquon Barkley wants to start having fun again.

Since returning from a high ankle sprain to his right ankle more than a month ago, Barkley has carried 64 times for 165 yards, an average of 2.57 yards. Against the Jets, he gained 1 yard on 13 carries, a career low.

Im just going to go out there and ball and have fun and go out there with my brothers, and whatever happens, happens, he said Thursday. Im not going to be worried about if hes hitting it too much or if hes not doing this or doing that. The reason I got drafted here is the reason Im one of the best running backs in the league, and Im just going to go out there and play and do what I do.

Heres what you need to know:

Who: New York Giants vs. Chicago Bears

What: NFL, Week 12

Where: Soldier Field, Chicago, Ill.

When: Sunday, Nov. 24, 2019

Time: 1 p.m. EDT

TV: Fox

Announcers: Thom Brenneman (play-by-play), Chris Spielman (analyst), Shannon Spake (sideline reporter)

Radio: WFAN

Announcers: Bob Papa (Play by play), Carl Banks (Color commentator), Howard Cross (sideline reporter)

Channel finder: Verizon Fios, AT&T U-verse, Comcast Xfinity, Spectrum/Charter,Optimum/Altice, DIRECTV, Dish, Hulu, fuboTV, Sling.

Live stream: Hulu, Sling

Betting line: Bears -6.5 | Get betting tips and analysis at nj.com/betting

GIANTS NOTES

QB DANIEL JONES (rookie) had 308 pass yards & 4 TDs vs. 0 INTs for 121.7 rating in Week 10. Is 1st rookie QB in NFL history with 2 games of 300+ pass yards & 4+ TDs. Has 13 TDs (11 pass, 2 rush) vs. 3 INTs for 101.9 rating in 4 career road starts.

RB SAQUON BARKLEY has 289 scrmimage yards (144.5 per game) & rec. TD in 2 career games vs. NFC North. Since 2018, ranks 3rd in NFL with 2,688 scrimmage yards. Has 16 games with 100+ scrimmage yards since 2018, tied-2nd most in NFL.

WR DARIUS SLAYTON (rookie) had career-highs in receptions (10) & rec. yards (121) & had 2 rec. TDs in Week 10. Aims for his 3rd in row on road with 2+ TD catches. Is only rookie in 2019 with 2 games of 2+ rec. TDs. WR GOLDEN TATE had 95 rec. yards & 2 TD catches in Week 10, his 7th career game with 2+ rec. TDs. Has 7+ receptions & 80+ rec. yards in 2 of his past 3 on road vs. NFC North. TE EVAN ENGRAM has rec. TD in 2 of his 3 career games vs. NFC North.

LB MARKUS GOLDEN had sack in Week 10. Has 4 sacks & FR-TD in his past 4 on road. LB ALEC OGLETREE is 1 of 3 LBs (JAMIE COLLINS & LAVONTE DAVID) with 10+ FFs (12) & 10+ INTs (11) since 2013. CB JANORIS JENKINS had 3 PD in last meeting. Aims for his 6th in row vs. Chi. with PD. Since 2012, ties for NFL lead with 102 PD. DT DALVIN TOMLINSON had career-high 9 tackles last week. Aims for his 3rd in row on road with sack. S ANTOINE BETHEA ranks 2nd among DBs in tackles (360) since 2016.

BEARS NOTES

QB MITCHELL TRUBISKY has 2+ TD passes in 2 of his past 3 starts at home. QB CHASE DANIEL had 2 TDs vs. 2 INTs for 89.7 rating in only start in 2019 (Week 5 vs. Oak.). Passed for career-hgh 285 yards & TD in last meeting.

RB TARIK COHEN had 74 scrimmage yards (39 rush, 35 rec.) & TD catch last week, his 9th career rec. TD. Aims for his 3rd in row with TD catch. Has 167 receptions since 2017, 4th-most among RBs. RB DAVID MONTGOMERY ranks 2nd among rookies in rush yards (497) & rush TDs (5) & ranks 3rd in scrimmage yards (649).

WR ALLEN ROBINSON aims for his 6th in row at home with 5+ receptions & 60+ rec. yards. Had 5 catches for 79 yards in last meeting. WR TAYLOR GABRIEL tied his career-high with 7 receptions & led team with 57 rec. yards last week. WR ANTHONY MILLER had career-high 6 receptions & had 54 rec. yards in Week 11.

LB KHALIL MACK had sack in last meeting. Aims for his 3rd in row vs. NYG with sack. Has 11 sacks & 6 FFs in 12 career home games with Chi. LB ROQUAN SMITH had 11 tackles & 2nd career INT last week. Aims for his 4th in row with 10+ tackles. LB LEONARD FLOYD had sack in last meeting. S EDDIE JACKSON had career-high 2 TFL & 4th career FF last week. S HA HA CLINTON-DIX had 4th career FR in Week 11. CB KYLE FULLER had 3 PD & INT in last meeting. Has 51 PD since 2017, most in NFL. -- NFL Communications

Follow this link:
Giants vs. Bears LIVE SCORE UPDATES and STATS (11/24/19) NFL Week 12 - NJ.com

Page 33«..1020..32333435..40..»

Home » Hgh » Page 33